Julie Rubinstein, President and COO of Adaptive Biotechnologies (ADPT), has been a consistent seller of company stock, with no open-market purchases recorded across her 97 total transactions. Her selling activity, concentrated entirely in ADPT, totals approximately $13.37 million, with the most recent cluster of 12 sales occurring between April 13 and April 27, 2026. These sales were executed in a steady cadence, ranging from roughly $47,000 to $453,000 per transaction, with the largest single sale of $453,595.06 occurring on April 21, 2026.
The pattern reveals a clear sell-side bias, as every open-market transaction (code "S") was a disposition of shares, while the corresponding exercise transactions (code "M") represent the mechanical conversion of options into stock—not discretionary purchases. Notably, the exercise values, typically around $124,548 per event, are consistently smaller than the accompanying sale values, indicating that Rubinstein is liquidating more shares than she is acquiring through option exercises. This is evident in the April 27 transaction, where she sold $270,896.51 worth of stock while exercising options valued at $124,421.22, a trend repeated across nearly every trading day in the period.
The absence of any "P" (purchase) codes or acquisitions (code "A") underscores that Rubinstein's activity is entirely divestiture-oriented, with no new cash committed to the company's shares. Her recent selling spree, spanning nine consecutive trading days, suggests a deliberate, systematic reduction of her position in ADPT, though the filings do not indicate whether this is part of a pre-arranged trading plan or a response to personal financial considerations. The data, however, is unambiguous: Rubinstein is a net seller, and her recent activity shows no sign of a shift toward accumulation.
AI-assisted summary